
Donna Marklew, an occupational therapist from Coventry, received a diagnosis of neuroendocrine cancer following a hysterectomy performed to address complications from childbirth. The cancer was identified when tissue samples extracted during the procedure at Warwick Hospital were examined after she experienced a uterine prolapse.
Neuroendocrine cancer is a rare condition affecting hormone-producing cells throughout the body. According to Neuroendocrine Cancer UK, the disease is estimated to impact 6,000 people annually in the UK. The charity’s chief executive noted that patients typically experience a five-year gap between initial symptoms and formal diagnosis, as the condition’s manifestations can mimic other illnesses, leading patients down alternative diagnostic pathways before the correct identification occurs.
Marklew’s case revealed tumors in her appendix, Fallopian tubes, and surrounding tissue. She underwent a nine-hour surgical procedure in March 2025 to remove as many tumors as possible. Following surgery, she requires three injections weekly to manage the disease and has recently begun Peptide Receptor Radionuclide Therapy administered four times weekly every two months. Her tumors are classified as grade two, meaning they grow relatively slowly, though progression continues.
Characterized as a complex and diverse cancer, neuroendocrine disease can develop in various body locations, most commonly in the lungs, digestive tract, and pancreas. The condition’s difficulty in detection stems partly from its ability to affect multiple organs and its non-obvious presentation. Marklew has highlighted particular diagnostic challenges for women and emphasizes the psychological impact of living with a largely unknown condition. She has since established support groups through Neuroendocrine Cancer UK, with sessions beginning in September, to provide community and understanding for affected individuals.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI